Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis
Maria Escala-Garcia(University of Cambridge), Anna Jakubowska(Pomeranian Medical University), Federico Canzian(German Cancer Research Center), Volker Arndt(German Cancer Research Center), Sander Canisius(University of Cambridge), A. Heather Eliassen(Brigham and Women's Hospital), Fergus J. Couch(Mayo Clinic), Peter A. Fasching(Universitätsklinikum Erlangen), Graham G. Giles(The University of Melbourne), Jose E. Castelao(Servicio Gallego de Salud), Jenny Chang‐Claude(Universität Hamburg), Manuela Gago-Domínguez(University of Southern California), Thilo Dörk(Hannover Re (Germany)), Melanie Gündert(German Cancer Research Center), Bernadette A. M. Heemskerk‐Gerritsen(Erasmus MC), Heiko Becher(Universität Hamburg), José Á. García-Sáenz(Hospital Clínico San Carlos), Joe Dennis(University of Cambridge), Jürgen Geisler(Oslo University Hospital), Alison M. Dunning(University of Cambridge), Kamila Czene(Karolinska Institutet), Arif B. Ekici(University Medical Center Groningen), Peter Devilee(Leiden University), Douglas F. Easton(University of Cambridge), Sabine Behrens(German Cancer Research Center), Per Hall(Karolinska Institutet), William Jacot(Inserm), Antoinette Hollestelle(Erasmus MC Cancer Institute), Christopher A. Haiman(University of Southern California), Stig E. Bojesen(University of Copenhagen), Renske Keeman(The Netherlands Cancer Institute), Montserrat García‐Closas(Institute of Cancer Research), Hermann Brenner(Universidad de Granada), Hoda Anton‐Culver(University of California, Irvine), Jaana M. Hartikainen(University of Eastern Finland), Mervi Grip(University of Oulu), Stephen J. Chanock(National Cancer Institute), Ute Hamann(German Cancer Research Center), Reiner Hoppe(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Niclas Håkansson(Cancer Prevention Institute of California), Matthias W. Beckmann, John L. Hopper(The University of Melbourne), David J. Hunter(Zhujiang Hospital), Mary B. Daly(Fox Chase Cancer Center), Henrik Flyger(Herlev Hospital), Manjeet K. Bolla(University of Cambridge), Annelie Augustinsson(Lund University), Jonathan Beesley(QIMR Berghofer Medical Research Institute), Marina Bermisheva(Russian Academy of Sciences)
Cited by 5
Related Papers
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
|JAMA Oncology|2016|6.3k
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
|The Lancet Public Health|2022|5.4k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k